2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.
Javier Martin-Broto, MD, PhD, medical oncologist, the University Hospital, leader, Villalba General Hospital, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.
MDM2 amplification is commonly seen in specific subtypes of soft tissue sarcoma, such as well-differentiated and dedifferentiated liposarcoma, which are some of the most common sarcoma subtypes, Martin-Broto says. The amplification of an extra chromosome is present in these subtypes of sarcomas, leading to patients with well-differentiated and dedifferentiated liposarcomas to experience the inactivation of p53, Martin-Broto explains.
When MDM2 is amplified, it causes the inactivation of p53, which plays a key role in controlling the cell, Martin-Broto continues. This is an underlying mechanism that makes targeted treatments vital for patients with soft tissue sarcomas, Martin-Broto concludes.